新冠病毒肺炎临床试验核心指标集
2021-01-25金鑫瑶庞博张俊华刘清泉杨忠奇封继宏刘学政张磊王保和黄宇虹Jn马玉玲Myn元唯安谢雁鸣唐健元高蕊杜亮张硕祁寒梅孙宇郑文科杨丰文蔡慧姿王可仪欧益黄明朱彦喻佳洁田金徽赵敏胡镜清姚晨李幼平张伯礼
金鑫瑶,庞博,张俊华,刘清泉,杨忠奇,封继宏,刘学政,张磊,王保和,黄宇虹,A Jn F,马玉玲,Myn S L,元唯安,谢雁鸣,唐健元,高蕊,杜亮,张硕,祁寒梅,孙宇,郑文科,杨丰文,蔡慧姿,王可仪,欧益,黄明,朱彦,喻佳洁,田金徽,赵敏,胡镜清,姚晨,李幼平,张伯礼
a Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China
b Chinese Clinical Trials Core Outcome Set Research Center, Tianjin 301617, China
c Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing 100010, China
d The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, China
e The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300150, China
f The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300201, China
g Istituto Superiore di Sanità, Rome 00161, Italy
h University of Oxford, Oxford OX1 3PT, UK
i Korea Institute of Oriental Medicine, Daejeon 34054, Republic of Korea
j Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200120, China
k Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China
l Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, China
m Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China
n The Chinese Cochrane Center, West China Hospital of Sichuan University, Chengdu 610041, China
o The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
p Suqian People’s Hospital of Nanjing Drum-Tower Hospital Group, Suqian 223800, China
q Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China
r Lanzhou University, Lanzhou 730000, China
s The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450099, China
t Institute of Basic Theory for Chinese Medicine, China Academy of Chinese Medicine Science, Beijing 100700, China
u Peking University First Hospital, Beijing 100034, China
1. 引言
医疗干预措施的有效性和安全性评价主要基于相关结局指标的测量和数据分析。然而国内外研究发现,临床研究采用的评价指标普遍存在不一致、不规范、不合理、不重要等问题,影响了研究结果的科学性和实用性,导致研究浪费[1–3]。为了解决上述问题,循证医学和临床研究方法学专家们提出了研制核心指标集(core outcome set, COS)的应对策略。COS是指健康或卫生保健等特定领域中所有临床研究都必须测量和报告的最少的、最重要的指标集合[4],旨在规范临床研究结局指标,提高研究结果的实用性、可比性和透明度[4]。2010年,有效性试验核心指标(core outcome measures in effectiveness trials, COMET)协作网成立,通过制定COS的方法学指南,致力于促进COS研究的质量。目前已发布了《有效性试验核心指标(COMET)手册》(1.0版)[5]、核心指标集的研制规范(Core Outcome Set-STAndards for Development, COS-STAD)[6]、核心指标集的报告规范(Core Outcome Set-STAndards for Reporting,COS-STAR)[7]和核心指标集研究方案报告条目(Core Outcome Set-STAndards Protocol Items,COS-STAP)[8]
等一系列研究技术指南。
自从新型冠状病毒肺炎(Coronavirus Disease 2019,COVID-19)疫情暴发以来,已有数百个临床试验方案完成注册,且部分临床试验已经开始实施招募患者。截至2020年2月20日,在www.chictr.org.cn和clinicaltrials.gov平台已有228个COVID-19临床试验完成注册。然而,这些已经注册的临床试验方案,尤其是方案中涉及的结局指标尚存在一些不足,如大部分的结局指标名称使用不规范,类似研究间结局指标的同质性差、缺乏临床重要性、指标的测量时点不清等。……
